PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED OR REFRACTORY SYSTEMIC ANAPLASTIC LARGE T‐CELL LYMPHOMA (ALCL) RECEIVING BRENTUXIMAB VEDOTIN AND OUTCOME AFTER TREATMENT FAILURE. (June 2017) - Oki, Y.; Feldman, T.; Chihara, D.; Sanchez, L.; Fanale, M.; Connors, J.M.; Wong, S.; Savage, K.J.